|
Topic 371 - Phase I SBIR Contract - Valudation and Optimization of RP-185 as Adjuvant to Exploit the Immune Response Generated by Radiation
|
261201800023C
|
$299,847
|
-, -
|
RIPTIDE BIOSCIENCE, INC.
|
|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S1
|
$120,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S2
|
$60,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S3
|
$118,652
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S4
|
$199,541
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-43
|
$3,792,720
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-09
|
$461,999
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-10
|
$461,172
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Center for Multiple Myeloma Nanotherapy
|
3U54CA199092-03S1
|
$29,864
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-03
|
$2,224,884
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-04
|
$2,184,301
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-07
|
$1,414,315
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-08
|
$1,347,488
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
1R03CA212798-01
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Novel Combinatorial Therapeutic Approach for Prostate Cancer
|
1R03CA219336-01
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
5R03CA212798-02
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Novel Combinatorial Therapeutic Approach for Prostate Cancer
|
5R03CA219336-02
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Analysis of HCC CTC Phenotype for Liver Transplant Candidate Selection
|
1R21CA216807-01A1
|
$203,254
|
AGOPIAN, VATCHE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-02
|
$474,276
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade
|
1R43CA228721-01
|
$299,607
|
AKPORIAYE, EMMANUEL
|
VEANA THERAPEUTICS, LLC
|
|
Single-Cell Measurement of Lipid Signaling in Colorectal Cancer
|
5R01CA177993-04
|
$584,480
|
ALLBRITTON, NANCY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Single-Cell Measurement of Lipid Signaling in Colorectal Cancer
|
5R01CA177993-05
|
$575,397
|
ALLBRITTON, NANCY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Dosage-Dependent Hedgehog Signaling in Pancreatic Cancer
|
5R01CA198074-03
|
$378,171
|
ALLEN, BENJAMIN
|
UNIVERSITY OF MICHIGAN
|
|
Dosage-Dependent Hedgehog Signaling in Pancreatic Cancer
|
5R01CA198074-04
|
$378,171
|
ALLEN, BENJAMIN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
|
5R01CA183811-04
|
$435,560
|
ALMAN, BENJAMIN
|
DUKE UNIVERSITY
|
|
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
|
5R01CA183811-05
|
$435,560
|
ALMAN, BENJAMIN
|
DUKE UNIVERSITY
|
|
Cell-cell communications create robust collective immunological responses
|
ZIA BC 011728
|
$198,401
|
Altan-Bonnet, Gregoire
|
CCR (NCI)
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-48S1
|
$142,498
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-48
|
$2,645,581
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Par-4 Regulation and Function in Breast Cancer Dormancy and Recurrence
|
3R01CA208042-03S1
|
$223,893
|
ALVAREZ, JAMES
|
DUKE UNIVERSITY
|
|
HLTF gene silencing: a novel determinant of sensitivity to autophagy inhibition
|
5R01CA169134-05
|
$312,942
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
The Molecular Profile of Prostate Tumors in African-American Men
|
ZIA BC 010624
|
$149,910
|
Ambs, Stefan
|
CCR (NCI)
|
|
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
|
5U01CA179671-04
|
$303,172
|
ANEJA, RITU
|
GEORGIA STATE UNIVERSITY
|
|
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
|
5U01CA179671-05
|
$303,118
|
ANEJA, RITU
|
GEORGIA STATE UNIVERSITY
|
|
Clinical trials in women's cancers
|
ZIA BC 011584
|
$192,282
|
Annunziata, Christina
|
CCR (NCI)
|
|
Immune cell control of ovarian cancer
|
ZIA BC 011775
|
$288,423
|
Annunziata, Christina
|
CCR (NCI)
|
|
Targeting the MET pathway in urothelial carcinoma
|
ZIA BC 011594
|
$497,661
|
Apolo, Andrea
|
CCR (NCI)
|
|
Stanford Cancer Institute
|
3P30CA124435-11S1
|
$248,520
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
3P30CA124435-11S2
|
$171,518
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
5P30CA124435-11
|
$3,334,464
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-08S1
|
$175,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-09S1
|
$249,371
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-08
|
$2,480,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-09
|
$2,480,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
T Cell Alternative p38 Activation Pathway
|
ZIA BC 010774
|
$298,466
|
Ashwell, Jonathan
|
CCR (NCI)
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|